ilShinbiobase일신바이오

ilShinbiobase reports strong trailing profits on falling revenue, while its share price has dropped sharply over the past year and sits near its 52-week low.

The company makes ultra-low temperature freezers and freeze dryers for labs and pharmaceutical and food production, and sells in many regions through its export subsidiary. For the twelve months to H1 2026 it reported revenue of about ₩15.8B... written correctly as ₩15.8B? Revenue is about ₩15.8B... see points for detail. The share price is ₩998, down 35.9% over one year, against a 52-week range of ₩851 to ₩2,055.

What stands out

• Trailing twelve-month revenue is ₩15.8B with operating income of ₩5.0B and net income of ₩6.0B, so net income is above operating income, which the filings do not explain in the data provided.
• Annual revenue fell in 2022, 2023 and 2024 but rose 34.3% in 2025 to ₩14.5B, and the 2026 trailing figures are still below the 2021 peak of ₩24.4B.
• Valuation metrics show a P/E of 7.3 and P/B of 0.7, with a DCF base fair value of ₩982 close to the current price; the bear and bull values are ₩687 and ₩1,457.
• Recent filings include a major sales or supply contract on 2 October 2026 and an amended version on 30 September, with no contract value given in the data.
• Foreign ownership fell from 3.6% to 2.8% over about 60 days, and net investor flows over 20 days were negative across foreign, institutional and retail buyers.

What to watch

• An August 2026 market notice flagged a designation concern for management issues because the share price was below ₩1,000; the data does not say what follow-up is required.
• Revenue has been volatile across years, so the next annual or quarterly results will show whether the 2025 growth holds.
• The data shows no borrowings and a debt-to-equity ratio of 10%, but no news headlines were available, so no recent news context is provided.